Anke Kuijpers

Dr. Anke Kuijpers


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2013 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
AKAnke Kuijpers
Anke Kuijpers
BMBoj Mirck
Boj Mirck
AAArend G. J. Aalbers
Arend G. J. Aalbers
SNSimon W. Nienhuijs
Simon W. Nienhuijs
IHIgnace de Hingh
Ignace de Hingh
VVVictor Jilbert Verwaal
Victor Jilbert Verwaal
This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metas

23 September 2014 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
AKAnke Kuijpers
Anke Kuijpers
AAArend G. J. Aalbers
Arend G. J. Aalbers
SNSimon W. Nienhuijs
Simon W. Nienhuijs
IHIgnace de Hingh
Ignace de Hingh
MWMarinus J. Wiezer
Marinus J. Wiezer
VVVictor Jilbert Verwaal
Victor Jilbert Verwaal

1 February 2016 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AKAnke Kuijpers
Anke Kuijpers
MHMichael Hauptmann
Michael Hauptmann
AAA.G. Aalbers
A.G. Aalbers
SNS.W. Nienhuijs
S.W. Nienhuijs
IHIgnace de Hingh
Ignace de Hingh
VVVictor Jilbert Verwaal
Victor Jilbert Verwaal

1 August 2014 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AKAnke Kuijpers
Anke Kuijpers
AMA.M. Mehta
A.M. Mehta
AAA.G.J. Aalbers
A.G.J. Aalbers
WDW.J. van Driel
W.J. van Driel
HBH. Boot
H. Boot
VVVictor Jilbert Verwaal
Victor Jilbert Verwaal

22 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AKAnke Kuijpers
Anke Kuijpers
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi
Melanoma treatment is leading the neo-adjuvant systemic (NAS) therapy field. It is hypothesized that having the entire tumor in situ, with all of the heterogeneous tumor antigens, allows the patient’s immune system to have a broader response to the tumor in all its shapes and forms. This translates into a higher clinical efficacy. Another benefit of NAS therapy potentially includes identifying patients who have a favorable response, which could offer an opportunity for the de-escalation of the extent of surgery and the need for adjuvant radiotherapy and/or adjuvant systemic therapy, as well as tailoring the follow-up in terms of the frequency of visits and cross-sectional imaging. In this paper, we will review the rationale for NAS therapy in resectable metastatic melanoma and the results obtained so far, both for immunotherapy and for BRAF/MEKi therapy, and discuss the response assessment and interpretation, toxicity and surgical considerations. All the trials that have been reported up to now have been investigator-initiated phase I/II trials with either single-agent anti-PD-1, combination anti-CTLA-4 and anti-PD-1 or BRAF/MEK inhibition. The results have been good but are especially encouraging for immunotherapies, showing high durable recurrence-free survival rates. Combination immunotherapy seems superior, with a higher rate of pathologic responses, particularly in patients with a major pathologic response (MPR = pathologic complete response [pCR] + near-pCR [max 10% viable tumor cells]) of 60% vs. 25–30%. The SWOG S1801 trial has recently shown a 23% improvement in event-free survival (EFS) after 2 years for pembrolizumab when giving 3 doses as NAS therapy and 15 as adjuvant versus 18 as adjuvant only. The community is keen to see the first results (expected in 2024) of the phase 3 NADINA trial (NCT04949113), which randomized patients between surgery + adjuvant anti-PD-1 and two NAS therapy courses of a combination of ipilimumab + nivolumab, followed by surgery and a response-driven adjuvant regimen or follow-up. We are on the eve of neo-adjuvant systemic (NAS) therapy, particularly immunotherapy, becoming the novel standard of care for macroscopic stage III melanoma.

24 March 2026 in European Journal of Cancer
Verified
Journal Article
Open access
MWMichael J. Wilson
Michael J. Wilson
ASAntonius W. Schurink
Antonius W. Schurink
YSYvonne Schrage
Yvonne Schrage
MWMichel Wouters
Michel Wouters
WHWinan J. van Houdt
Winan J. van Houdt
AKAnke Kuijpers
Anke Kuijpers
Neoadjuvant immunotherapy is increasingly used in resectable stage III melanoma, with major pathological response (MPR) closely linked to improved outcomes. Predictive biomarkers are needed to identify responders and potentially allow surgical de-escalation. [¹⁸F]FDG-PET/CT is a non-invasive method to assess metabolic response, and the index lymph node (ILN) may reflect response of the entire nodal bain. This retrospective analysis of largely prospectively collected data included patients with resectable stage III melanoma treated with two cycles of neoadjuvant pembrolizumab at two Dutch melanoma centres. [¹⁸F]FDG-PET/CT was performed before and after treatment, with metabolic response classified using EORTC criteria. Volumetric PET parameters, metabolic tumour volume (MTV) and total lesion glycolysis (TLG), were analysed retrospectively. Pathological response was assessed according to INMC criteria. In patients undergoing therapeutic lymph node dissection, ILN response was compared with the entire nodal basin. Forty-seven patients initiated neoadjuvant pembrolizumab, and 39 underwent surgery. Twenty-four patients had evaluable PET/CT scans: complete metabolic response (CMR) in 12.5%, partial metabolic response (PMR) in 37.5%, stable disease in 16.7%, and progressive metabolic disease (PMD) in 33%. Overall, 59% achieved MPR. All patients with CMR achieved MPR; 64% with PMR achieved MPR, compared with only 12.5% with PMD. All patients with pathological complete or near-complete response showed reductions in both ΔTLG and ΔMTV. ILN response was fully concordant with total nodal basin response in all evaluable cases. Three patients who declined surgery after CMR remained recurrence-free during follow-up. Metabolic response on [¹⁸F]FDG-PET/CT, particularly CMR, strongly correlates with pathological response after neoadjuvant pembrolizumab. ILN response accurately reflects total nodal basin response, supporting response-adapted surgical strategies.